Harry Brown
Psychiatric/Mental Health · Houma, LANPI 1144877978
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 400 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$805
- Teva Pharmaceuticals USA, Inc.$629
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,02298%
- Education$2072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,627 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $1,297 |
| Vanda Pharmaceuticals Inc. | 41 | $1,068 |
| Neurocrine Biosciences, Inc. | 49 | $1,054 |
| Alkermes, Inc. | 43 | $805 |
| Teva Pharmaceuticals USA, Inc. | 32 | $629 |
| Otsuka America Pharmaceutical, Inc. | 24 | $620 |
| Johnson & Johnson | 18 | $381 |
| Axsome Therapeutics, Inc. | 6 | $288 |
| E.r. Squibb & Sons, L.L.C. | 16 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $176 |
| Corium, LLC | 14 | $176 |
| Sunovion Pharmaceuticals Inc. | 12 | $167 |
| Ironshore Pharmaceuticals Inc. | 6 | $106 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Gilead | 1 | $99 |
| Merck | 5 | $98 |
| Lundbeck LLC | 6 | $83 |
| Indivior Inc. | 3 | $52 |
| Viiv Healthcare Company | 1 | $34 |
| Exact Sciences | 1 | $20 |
| Abbott | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Braeburn Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,230 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 134 | $194,287 |
| IngrezzaValbenazine Tosylate | 15 | $117,155 |
| CaplytaLumateperone Tosylate | 19 | $33,308 |
| FanaptIloperidone | 11 | $23,300 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $17,866 |
| ViibrydVilazodone Hcl | 23 | $8,049 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,951 |
| Oxtellar XrOxcarbazepine | 11 | $4,168 |
| Oxcarbazepine | 82 | $3,198 |
| Clonazepam | 273 | $2,742 |
| Trazodone Hcl | 241 | $2,196 |
| Lisdexamfetamine Dimesylate | 12 | $1,958 |
| Quetiapine Fumarate | 149 | $1,358 |
| Mirtazapine | 108 | $1,197 |
| Buspirone Hcl | 102 | $1,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $1,627 | $202,336157 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,054 | $117,15515 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,297 | $33,30819 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,068 | $23,30011 claims |
| Alkermes, Inc.Lybalvi | $805 | $17,86612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $176 | $6,95112 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $100 | $4,16811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Houma
- Amanda EymardHouma$617K
- Timothy PellegrinHouma$210K
- Amy LacoutureBaton Rouge$663K
- Amber LittlefieldBroussard$225K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
- Michelle DyerLake Charles$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.